Berlex Laboratories has signed a four-year agreement to supply New York Medical Imaging with Ultravist, an x-ray diagnostic contrast agent. The contract has a projected value of more than $6 million in
Berlex Laboratories has signed a four-year agreement to supply New York Medical Imaging with Ultravist, an x-ray diagnostic contrast agent. The contract has a projected value of more than $6 million in sales.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.